Get the Stockscreener App
17.00
0.18%
0.03
Crescent Biopharma Inc stock is traded at $17.00, with a volume of 129.67K.
It is up +0.18% in the last 24 hours and up +4.29% over the past month.
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent's pipeline product CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. The company focuses on advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.
See More
Previous Close:
$16.97
Open:
$17.12
24h Volume:
129.67K
Relative Volume:
0.40
Market Cap:
$631.45M
Revenue:
$11.88M
Net Income/Loss:
$-162.08M
P/E Ratio:
-1.3617
EPS:
-12.484
Net Cash Flow:
$-156.43M
1W Performance:
+1.86%
1M Performance:
+4.29%
6M Performance:
+36.11%
1Y Performance:
+15.65%
1-Day Range:
$16.87
$17.66
1-Week Range:
$16.03
$17.66
52-Week Range:
$8.72
$27.41
Crescent Biopharma Inc Stock (CBIO) Company Profile
Name
Crescent Biopharma Inc
Sector
Industry
Phone
617-430-5595
Address
300 FIFTH AVENUE, WALTHAM, CA
Compare CBIO vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CBIO
Crescent Biopharma Inc
|
17.00 | 602.85M | 11.88M | -162.08M | -156.43M | -12.48 |
VRTX
Vertex Pharmaceuticals Inc
|
552.85 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
833.56 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,019.49 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
158.83 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
211.38 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Crescent Biopharma Inc Stock (CBIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-28-26 | Initiated | Piper Sandler | Overweight |
| Jan-21-26 | Initiated | Guggenheim | Buy |
| Aug-25-25 | Initiated | Jefferies | Buy |
| Aug-11-25 | Initiated | H.C. Wainwright | Buy |
| Jul-14-25 | Initiated | Wedbush | Outperform |
| Jun-25-25 | Initiated | Stifel | Buy |
| Mar-21-25 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-11-25 | Initiated | Noble Capital Markets | Outperform |
| Jul-26-24 | Downgrade | TD Cowen | Buy → Hold |
| Dec-22-23 | Initiated | CapitalOne | Overweight |
| Nov-12-21 | Upgrade | Jefferies | Hold → Buy |
| Apr-29-21 | Resumed | Stephens | Overweight |
| Feb-10-21 | Initiated | Piper Sandler | Overweight |
| May-21-20 | Initiated | Raymond James | Outperform |
| Nov-14-19 | Initiated | ROTH Capital | Buy |
| Aug-05-19 | Downgrade | Jefferies | Buy → Hold |
| Aug-05-19 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Aug-05-19 | Downgrade | SunTrust | Buy → Hold |
| Apr-12-19 | Initiated | Piper Jaffray | Overweight |
| Jan-04-19 | Initiated | Oppenheimer | Outperform |
| Dec-18-18 | Initiated | H.C. Wainwright | Buy |
| Feb-12-18 | Reiterated | B. Riley FBR, Inc. | Buy |
| Feb-09-18 | Reiterated | Chardan Capital Markets | Buy |
| Dec-08-17 | Initiated | B. Riley FBR, Inc. | Buy |
| Jun-12-17 | Initiated | Chardan Capital Markets | Buy |
| Jun-06-17 | Initiated | Ladenburg Thalmann | Buy |
| Jul-26-16 | Initiated | SunTrust | Buy |
| Jun-30-16 | Initiated | Rodman & Renshaw | Buy |
| Mar-17-15 | Reiterated | Stifel | Buy |
View All
Crescent Biopharma Inc Stock (CBIO) Latest News
Crescent Biopharma, Inc. (NASDAQ:CBIO) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Balyasny Asset Management L.P. Expands Stake in Crescent Biophar - GuruFocus
Crescent Biopharma (NASDAQ:CBIO) Stock Price Up 4.9%Should You Buy? - MarketBeat
Balyasny Asset Management (CBIO) discloses 6.03% Crescent Biopharma ownership - Stock Titan
Crescent Biopharma (NASDAQ:CBIO) Shares Gap DownShould You Sell? - MarketBeat
Crescent Biopharma (CBIO) Shares Dip 2.86% as Stock Approaches Key $16 Support LevelDay Trade Opportunities - vinanet.vn
Crescent Biopharma Ord Shs (CBIO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
CBIO Q2 2026 Earnings: Narrower-Than-Expected Loss Buoys SharesRevenue Miss Report - vinanet.vn
Q3 EPS Forecast for Crescent Biopharma Lowered by Analyst - marketbeat.com
Analysts Offer Insights on Healthcare Companies: Dyne Therapeutics (DYN) and Crescent Biopharma (CBIO) - The Globe and Mail
Crescent Biopharma Announces Grants of Inducement Awards - The Manila Times
CRESCENT BIOPHARMA, INC. SEC Filing (Aug 3, 2026) - Stock Titan
Perceptive Advisors LLC Lowers Stake in Crescent Biopharma, Inc. $CBIO - MarketBeat
Crescent Biopharma (CBIO) Gets a Buy from Wedbush - The Globe and Mail
Crescent Biopharma Announces Q2 2026 Financial Results and Operational Update - Kalkine Media
Crescent Biopharma Reports Q2 2026 Results and Advances Clinical Development of CR-001, CR-002 and CR-003 - Quiver Quantitative
Crescent Biopharma: Q2 Earnings Snapshot - KING5.com
Crescent Biopharma posts $24.8 million Q2 net loss - Quiver Quantitative
Crescent Biopharma Reports Second Quarter 2026 Financial Results and Recent Business Highlights - GlobeNewswire
Crescent Biopharma Q2 Results: EPS beats estimates, losses narrow - scanx.trade
Exome Asset Management LLC Makes New $2.81 Million Investment in Crescent Biopharma, Inc. $CBIO - MarketBeat
Crescent Biopharma Ord Shs (CBIO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Crescent Biopharma Market Sentiment - Benzinga España
Crescent Biopharma, Inc. (NASDAQ:CBIO) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Crescent Biopharma Ord Shs (CBIO) Institutional Confidence - TradingKey
Crescent Biopharma (CBIO) Faces Selling Pressure, Testing Key Support After 4.29% DeclineTechnical Analysis - dars.gov.et
CBIO|Crescent Biopharma Ord Shs|Price:16.300|Chg%:-0.730 - TradingKey
Crescent Biopharma (CBIO) Shares Dip 4.3% as Stock Pulls Back Toward Key SupportDefined Outcome ETF - dars.gov.et
Crescent Biopharma grants inducement stock options for 52,500 shares at $15.83 each - Bitget
Two Crescent Biopharma Employees Receive 52,500 Stock Options - Stock Titan
CBIO Q1 2026 Earnings: Narrower-Than-Expected Loss Delivers Positive Surprise as Pipeline Progress ContinuesRevenue Inflection Point - vinanet.vn
CBIO Options Volatility — NASDAQ:CBIO - TradingView
Jennison Associates LLC Invests $2.81 Million in Crescent Biopharma, Inc. $CBIO - MarketBeat
Fairmount Healthcare Fund II LP acquires 853,450 Crescent Biopharma shares for $12.38 million - Bitget
Fairmount Funds' $12 Million Bet on Crescent Biopharma: A Strong Signal Amidst Volatility - Kavout | AI
Insider fund at Crescent Biopharma (NASDAQ: CBIO) buys 1.38M shares, warrants - Stock Titan
Fairmount Funds holds 16.5% of Crescent Biopharma (CBIO) after July 2026 deal - Stock Titan
CBIO Q1 2026 Earnings: Better-than-Expected Loss as Biotech Continues DevelopmentInvestor Earnings Call - vinanet.vn
Analysts Offer Insights on Healthcare Companies: RxSight (RXST), Kazia Therapeutics (KZIA) and Crescent Biopharma (CBIO) - The Globe and Mail
Crescent Biopharma (CBIO) Jefferies Global Healthcare Conference 2026 Summary - Quartr
Crescent Biopharma Announces Closing of Public Offering of Ordinary Shares and Pre-Funded Warrants, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares - The Manila Times
Crescent Biopharma closes $143.7 million public offering - Investing.com
Crescent Biopharma closes $143.7 million public offering By Investing.com - Investing.com Nigeria
Crescent Biopharma (CBIO) Proxy filing Summary - Quartr
Press Release: Crescent Biopharma Announces Closing of Public Offering of Ordinary Shares and Pre-Funded Warrants, Including Full Exercise of Underwriters' Option to Purchase Additional Shares - Moomoo
Crescent Biopharma (CBIO) Bank of America Global Healthcare Conference 2026 Summary - Quartr
H.C. Wainwright Maintains Crescent Biopharma(CBIO.US) With Hold Rating - Moomoo
Form 424B5 Crescent Biopharma Inc For: 15 July By Investing.com - Investing.com Canada
Crescent Bi raises up to $133.5M in registered offering of 8.09M shares and pre-funded warrants - TradingView
Crescent Biopharma (Nasdaq: CBIO) prices $125.0 million stock and warrant sale - Stock Titan
Form 424B5 CRESCENT BIOPHARMA, INC. - StreetInsider
Crescent Biopharma Inc Stock (CBIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.07%
1.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):